UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange
Act of 1934
JULY 20, 1998
--------------
(Date of earliest event reported)
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Exact name of registrant as specified in its charter)
DELAWARE 1-11353 13-3757370
-------- ------- ----------
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
358 SOUTH MAIN STREET, BURLINGTON, NORTH CAROLINA 27215
-------------------------------------------------------
(Address of principal executive offices)
336-229-1127
------------
(Registrant's telephone number, including area code)
<PAGE>
<PAGE>
ITEM 5. OTHER EVENTS
On July 20, 1998, Laboratory Corporation of America Holdings
(the "Company") issued a press release announcing that the
Antivirogram-TM- and the VircoGEN-TM-, two new diagnostic
testing procedures enabling physicians to evaluate resistance
of HIV to antiretroviral drugs, are now available for commercial
use exclusively from the Company's facilities in the U.S.
These new testing systems are an important advance in optimizing
treatment choices in the fight against HIV/AIDS.
ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL
INFORMATION AND EXHIBITS
(c) Exhibit
20 Press release of the Company dated July 20, 1998.
<PAGE>
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities and Exchange
Act of 1934, the registrant has duly caused this report to
be signed on its behalf by the undersigned hereunto duly
authorized.
LABORATORY CORPORATION OF AMERICA HOLDINGS
------------------------------------------
(Registrant)
By:/s/ Bradford T. Smith
-------------------------------
Bradford T. Smith
Executive Vice President,
General Counsel, Secretary
and Compliance Officer
Date: August 17, 1998
<PAGE>
<PAGE>
INVESTORS CONTACT: PAMELA SHERRY
336.584.5171, EXT. 4855
MEDIA CONTACT: HAYLEY SOFFER, MS&L SARRA SCHAAB, MS&L
212.213.7067 212.213.7056
HIV DRUG RESISTANCE TESTING PROCEDURES
NOW AVAILABLE IN THE UNITED STATES
--CLINICAL TRIALS INDICATE RESISTANCE TESTING PREDICTS
EFFECTIVENESS OF DRUG THERAPY--
Burlington, NC, July 20, 1998 - Laboratory Corporation of America-Registered
Trademark-Holdings (LabCorp-Registered Trademark-) (NYSE:LH) and VIRCO, today
announced that the Antivirogram-Trademark- and the VircoGEN-Trademark, two new
diagnostic testing procedures enabling physicians to evaluate resistance of
HIV to antiretroviral drugs, are now available for commercial use exclusively
from LabCorp facilities in the U. S. These new testing systems are an
important advance in optimizing treatment choices in the fight against
HIV/AIDS.
"Testing resistance in the clinical setting empowers physicians and patients
to make rational decisions about drug therapy," said John Mellors, M.D.
director of the AIDS Program, University of Pittsburgh Medical Center.
"Knowing which medications are most likely to be effective against the HIV
virus prior to treatment permits us to make better informed choices."
Data shows a promising indication of the testing systems' ability to predict
response to therapy. In outcomes studies using the Antivirogram-Trademark-
and VircoGEN-Trademark-, physicians were able to predict antiviral response
in antiretroviral experienced patients. One study done in collaboration with
the British Columbia Centre for Excellence in HIV/AIDS of 84 patients with
extensive prior nucleoside experience, found that patients with "sensitive"
virus, as indicated by phenotypic testing, (sensitivity being defined as the
ability of drugs to inhibit the virus) were twelve times more likely to
respond to ritonavir/saquinavir therapy.
- -more-
<PAGE>
<PAGE>
Patients whose virus was classified "sensitive" by genotypic testing, were
four times more likely to respond to the therapy. The study included protease
inhibitor (PI)-experienced patients that were switching to the PI combination
ritonavir/saquinivir alone or in combination with other antiretroviral therapy
as salvage therapy. Phenotyping and genotyping were conducted on isolates
from these patients using the Antivirogram-Trademark- and VircoGEN-Trademark-.
"Since the partnership between VIRCO and LabCorp was announced, our team of
scientists have been working diligently to bring the Antivirogram-Trademark-
and VircoGEN-Trademark- to market," said Dr. Myla Lai-Goldman, Executive Vice
President, Chief Scientific Officer and Medical Director of LabCorp. "The
data validates the clinical importance of these systems and we are committed
to continuing our ongoing work to assess their broad capabilities."
To further substantiate the value of these testing procedures, a large study
of 1500 isolates collected from the patients provided an impressive data set
to correlate genotypic resistance patterns with phenotypic resistance
profiles. While genotyping examines the drug resistance mutations accumulated
by the virus and may give an important indication of the possible evolution of
resistance, phenotyping measures virus growth in the presence of a drug. When
used together, physicians can now assess how each patient is going to respond
to given therapy, thus allowing physicians to make more informed decisions
when selecting potent therapeutic regimens.
Turnaround time for the VicoGEN-Trademark- is five to 10 working days and
three to four weeks for the Antovirogram-Trademark-. LabCorp customer service
is available to provide additional information by calling 800-533-0567.
ABOUT THE COMPANIES
- -------------------
Laboratory Corporation of America-Registered Trademark- Holdings (LabCorp-
Registered Trademark-) is a national clinical laboratory organization with
revenues of $1.5 billion in 1997. The Company operates primary testing
facilities nationally, offering more than 1,700 different clinical assays,
from routine blood analyses to more sophisticated technologies. LabCorp
performs diagnostic tests and procedures for physicians, managed-care
organizations, hospitals, clinics, long-term facilities, industrial companies,
and other clinical laboratories.
VIRCO is a privately-held high tech/molecular biology company that was founded
in 1995 by Rudi Pauwels, Ph.D. and Paul Stoffels, M.D. in Belgium, and Brendan
Larder, Ph.D. in the U.K. VIRCO specializes in genomics and bioinformatics
applied to disease management and is at the forefront of the development and
implementation of complex technologies to monitor HIV drug sensitivity in
infected persons. VIRCO's scientists have extensive experience in the field
of antiviral development and drug resistance, having performed phenotypic
resistance testing on more than 8,000 samples.
# # #
